Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide,
ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that
remains (residual) after donor stem cell transplant. Lenalidomide may help the immune system
kill abnormal blood cells or cancer cells and may also prevent the growth of new blood
vessels that are needed for cancer growth. Ixazomib citrate may stop the growth of cancer
cells by interfering with proteins necessary for cell growth. Drugs used in chemotherapy,
such as dexamethasone, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. It is
not yet known whether lenalidomide is more effective with or without ixazomib citrate and
dexamethasone in treating residual multiple myeloma.